Claims for Patent: 4,112,068

Summary for Patent: 4,112,068

Title:	Canine lung cell strain culture systems and processes for the cultivation of viruses and vaccines therefrom
Abstract:	A finite cell strain is derived from canine fetal lung tissue, the cells of which are fibroblast-like, diploid, and are free of reverse transcriptase and C-type particles. With a nutrient medium the cells provide a cell culture system useful in the cultivation of a number of viruses from which vaccines may be prepared.
Inventor(s):	Cabasso; Victor J. (Moraga, CA)
Assignee:	Cutter Laboratories, Inc. (Berkeley, CA)
Application Number:	05/828,369
Patent Claims:	1. A process for the preparation of a vaccine which comprises: (a) maintaining a culture of diploid fibroblast-like cells of a finite cell strain derived from fetal canine lung tissue in a nutrient culture medium, said cells being free of reverse transcriptase and C-type particles, being free of adventitious viruses, being non-oncogenic, and remaining diploid throughout their passage range; (b) inoculating said medium with a virus selected from the group consisting of rabies virus, infectious bovine rhinotracheitis virus, canine distemper virus, type 3 parainfluenza virus and bluetongue virus; (c) cultivating said virus in said medium; and, (d) recovering a harvest of said virus therefrom. 2. The process of claim 1 further including the step of rendering the virus non-infective in said harvest. 3. The process of claim 2 wherein said rabies virus includes the PV-12 strain of rabies virus. 4. A vaccine suitable for use in an animal to stimulate the production of antibodies when obtained by the process of claim 1. 5. A rabies vaccine when obtained by the process of claim 2. 6. A rabies vaccine when obtained by the process of claim 1 wherein the virus used for inoculation of the medium in step (b) is an attenuated rabies virus. 7. A process for the preparation of a rabies vaccine which comprises: (a) maintaining a culture of diploid fibroblast-like cells of a finite cell strain in a nutrient culture medium, said cells being derived from fetal canine lung tissue and further characterized as being free of reverse transcriptase and C-type particles, free of adventitious viruses, being non-oncogenic, and remaining diploid throughout their passage range; (b) inoculating a first portion of said cell culture with a rabies virus; (c) serially passaging said virus for a number of passages sufficient to effect adaptation of said virus to said cells; (d) inoculating a second portion of said cell culture with said adapted rabies virus; (e) cultivating said adapted rabies virus; and, (f) harvesting the cultivation of said adapted rabies virus. 8. The process of claim 7 wherein said rabies virus used in step (b) is selected from the group consisting of HEP Flury and PV-12 strains of rabies virus. 9. A rabies vaccine when obtained by the process of claim 7. 10. A rabies vaccine when obtained by the process of claim 8.

Details for Patent 4,112,068

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bavarian Nordic A/s	RABAVERT	rabies vaccine	For Injection	103334	10/20/1997		1995-09-05
Sanofi Pasteur Sa	IMOVAX RABIES	rabies vaccine	For Injection	103931	02/04/2000		1995-09-05